Recent Finacing
Recent Raise
Foresight Diagnostics develops the PhasED-Seq/CLARITY liquid biopsy platform for ultrasensitive ctDNA minimal residual disease testing, operating a CLIA laboratory and scaled automation to support oncology clinical and diagnostic use.
